ArticleRenal failure2026
Peripheral B-cell receptor immunoglobulin heavy chain repertoire as a potential biomarker for frequently relapsing nephrotic syndrome in children.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the distribution characteristics of the peripheral blood B cell receptor (BCR) repertoire immunoglobulin heavy chain (IGH) in children with frequently relapsing nephrotic syndrome (FRNS), explore its dynamic changes before and after glucocorticoid therapy, and evaluate its potential value as a biomarker for predicting FRNS.
methods35 newly diagnosed children with primary nephrotic syndrome (PNS) admitted to Xuzhou Medical University Affiliated Hospital from September 2024 to September 2025 were divided into the FRNS group (
resultsBefore glucocorticoid treatment, compared with the NFRNS group, the FRNS group showed significantly increased IGH gene usage bias, shorter CDR-H3 length, higher SHM, and decreased BCR repertoire diversity (all
conclusionCharacteristics of the IGH repertoire in FRNS patients, especially the Shannon index, may serve as potential biomarkers for early risk stratification and personalized treatment of PNS in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.